Systemic inflammation, blood-brain barrier vulnerability and cognitive / non-cognitive symptoms in Alzheimer disease: Relevance to pathogenesis and therapy

Frontiers in Aging Neuroscience

Volumn 6, Issue JUL, 2014, Pages

  Takeda, Shuko ^a,b   Sato, Naoyuki ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer disease; Blood brain barrier; Pathogenesis; Systemic inflammation; Therapy

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DEMENTIA ASSOCIATED BEHAVIORAL DISTURBANCE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; MENTAL DETERIORATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; SYSTEMIC INFLAMMATION;

EID: 84904654930     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00171     Document Type: Article

References (105)

1. Thies W, Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. Mar 2013;9(2):208-245.
2. Iqbal K, Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis. 2006;9(3 Suppl):219-242.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. Jul 19 2002;297(5580):353-356.
4. Delrieu J, Ousset PJ, Caillaud C, Vellas B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem. Jan 2012;120 Suppl 1:186-193.
5. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. Mar 2008;4(2):65-79.
6. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. May-Jun 2000;21(3):383-421.
7. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem Soc Trans. Aug 2011;39(4):898-901.
8. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res. Oct 2010;33(10):1539-1556.
9. Serrano-Pozo A, Muzikansky A, Gomez-Isla T, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol. Jun 2013;72(6):462-471.
10. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. May 22 2013;78(4):631-643.
11. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci. Jul 2013;16(7):848-850.
12. Sato N, Takeda S, Uchio-Yamada K, et al. Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci. Jul 2011;4(2):118-127.
13. Takeda S, Sato N, Ogihara T, Morishita R. The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential. Front Biosci. 2008;13:2253-2265.
14. Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci. 2013;5:64.
15. Iadecola C. The pathobiology of vascular dementia. Neuron. Nov 20 2013;80(4):844-866.
16. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. Sep 2010; 120(3):287-296.
17. Muresanu DF, Popa-Wagner A, Stan A, Buga AM, Popescu BO. The vascular component of Alzheimer's disease. Curr Neurovasc Res. May 2014;11(2):168-176.
18. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. Apr 13 2010;107(15):7036-7041.
19. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R. Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol Aging. Aug 2013;34(8):2064-2070.
20. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. May 2009;30(5):759-768.
21. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. Jan 1993;7(1):75-83.
22. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 1989;77(6):569-575.
23. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron. Feb 16 2006;49(4):489-502.
24. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol. Mar 1996;55(3):273-279.
25. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol. Mar 1995;54(2):276-281.
26. Bauer J, Strauss S, Schreiter-Gasser U, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. Jul 8 1991;285(1):111-114.
27. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. Jul 1999;19(4):223-230.
28. van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport. Jan 1993;4(1):69-72.
29. Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. Jan 1998;152(1):307-317.
30. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation. Oct 18 2005;2:23.
31. Matsuoka Y, Picciano M, Malester B, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. Apr 2001;158(4):1345-1354.
32. Sheng JG, Mrak RE, Bales KR, et al. Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. J Neurochem. Jan 2000;74(1):295-301.
33. Ji B, Maeda J, Sawada M, et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci. Nov 19 2008;28(47):12255-12267.
34. Maeda J, Ji B, Irie T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci. Oct 10 2007;27(41):10957-10968.
35. Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. Sep-Oct 1996;17(5):761-766.
36. Craft JM, Watterson DM, Hirsch E, Van Eldik LJ. Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation. Jun 20 2005;2:15.
37. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest. Jun 2007;117(6):1595-1604.
38. Chakrabarty P, Jansen-West K, Beccard A, et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. Feb 2010;24(2):548-559.
39. Ghosh S, Wu MD, Shaftel SS, et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci. Mar 13 2013;33(11):5053-5064.
40. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. Aug 1996;47(2):425-432.
41. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. Aug 1 2000; 20(15):5709-5714.
42. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. Nov-Dec 2001;22(6):983-991.
43. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. Aug 20 2003;23(20):7504-7509.
44. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. Jan 1995;45(1):51-55.
45. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. Feb 1994;44(2):227-232.
46. Trepanier CH, Milgram NW. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy? J Alzheimers Dis. 2010;21(4):1089-1099.
47. McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging. Jul 2000;17(1):1-11.
48. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. Aug 1993;43(8):1609-1611.
49. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. Jul 13 1999;53(1):197-201.
50. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. Jun 4 2003;289(21):2819-2826.
51. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. Jan 13 2004;62(1):66-71.
52. Shrestha R, Millington O, Brewer J, Bushell T. Is central nervous system an immune-privileged site? Kathmandu Univ Med J (KUMJ). Jan-Mar 2013;11(41):102-107.
53. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. Aug 2007;21(6):727-735.
54. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. Apr 24 2007;68(17):1411-1416.
55. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. Nov 2004;35(11 Suppl 1):2616-2619.
56. Dunn N, Mullee M, Perry VH, Holmes C. Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord. Apr-Jun 2005;19(2):91-94.
57. Sundelof J, Kilander L, Helmersson J, et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis. 2009;18(1):79-87.
58. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. Apr 2013;68(4):433-440.
59. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. May 2000;157(5):708-714.
60. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. Jan 2001;16(1):39-44.
61. Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry. Nov 2005;13(11):976-983.
62. Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disease. Curr Opin Psychiatry. May 2013;26(3):252-259.
63. Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer's disease. Curr Treat Options Neurol. Apr 2012;14(2):113-125.
64. van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet. Feb 27 2010;375(9716):773-775.
65. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive Care Med. Jun 2007;33(6):941-950.
66. Kat MG, Vreeswijk R, de Jonghe JF, et al. Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. Dement Geriatr Cogn Disord. 2008;26(1):1-8.
67. Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience. Jan 1999;88(1):193-200.
68. Godbout JP, Chen J, Abraham J, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. Aug 2005;19(10):1329-1331.
69. Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am. May 2009;29(2):321-337.
70. Vloeberghs E, Van Dam D, Franck F, Staufenbiel M, De Deyn PP. Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behav Brain Res. Jun 18 2007;180(2):146-151.
71. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci. Nov 2004;20(10):2757-2766.
72. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. Mar 26 2014.
73. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. Mar 2011;12(3):169-182.
74. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. Dec 2011;12(12):723-738.
75. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. Jul 2009;118(1):103-113.
76. Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem. 2006;13(15):1757-1775.
77. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. Jan 2006;7(1):41-53.
78. Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem. May 1990;54(5):1798-1801.
79. McAllister MS, Krizanac-Bengez L, Macchia F, et al. Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res. Jun 15 2001;904(1):20-30.
80. Bartels AL. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des. 2011;17(26):2771-2777.
81. Chung YC, Ko HW, Bok E, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep. Apr 2010;43(4):225-232.
82. Tourdias T, Dousset V. Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. Neurotherapeutics. Jan 2013;10(1):111-123.
83. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. Nov 5 2012;8(11):647-656.
84. Prineas JW, Parratt JD. Oligodendrocytes and the early multiple sclerosis lesion. Ann Neurol. Jul 2012;72(1):18-31.
85. Winkler EA, Sengillo JD, Sagare AP, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. Mar 3 2014.
86. Garbuzova-Davis S, Sanberg PR. Blood-CNS Barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.
87. Rodrigues MC, Hernandez-Ontiveros DG, Louis MK, et al. Neurovascular aspects of amyotrophic lateral sclerosis. Int Rev Neurobiol. 2012;102:91-106.
88. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. Mar 2003;34(3):806-812.
89. Skoog I, Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res. Sep 2003;25(6):675-680.
90. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. Dec 10 1999;53(9):1937-1942.
91. Gentile MT, Poulet R, Di Pardo A, et al. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging. Feb 2009;30(2):222-228.
92. Takeda S, Sato N, Takeuchi D, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension. Dec 2009;54(6):1345-1352.
93. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. May 2009;10(5):333-344.
94. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology. 2010;67(1):122-131.
95. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences. April 21, 2009 2009;106(16):6820-6825.
96. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. May 24 2012;485(7399):512-516.
97. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. Dec 2003;10(6):463-470.
98. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. Mar 2006;20(3):426-433.
99. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. Nov 15 2002;298(5597):1379.
100. Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. Jan 19 2005;25(3):629-636.
101. Burbach GJ, Vlachos A, Ghebremedhin E, et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging. Feb 2007;28(2):202-212.
102. Luo F, Rustay NR, Seifert T, et al. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. J Pharmacol Exp Ther. Dec;335(3):580-588.
103. Vagnucci AH, Jr., Li WW. Alzheimer's disease and angiogenesis. Lancet. Feb 15 2003;361(9357):605-608.
104. Suhara T, Magrane J, Rosen K, et al. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging. May-Jun 2003;24(3):437-451.
105. Hayashi S, Sato N, Yamamoto A, et al. Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler Thromb Vasc Biol. Nov 2009;29(11):1909-1915.